Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®

Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®

Bibliographic Details
Main Authors:	Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, Claudio Gasperini, Enrico Montanari, Pierluigi Navarra, Francesco Patti, Maria Pia Sormani, Angelo Ghezzi
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2018-11-01
Series:	Neurology and Therapy
Subjects:	Bioequivalence Copemyl® Equivalence trials Glatiramoid Glatiramer acetate Multiple sclerosis
Online Access:	http://link.springer.com/article/10.1007/s40120-018-0116-x

Similar Items

Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
by: Giancarlo Comi, et al.
Published: (2018-11-01)

Approaches to the definition of macromolecular aggregates in glatiramoids
by: Yu. V. Olefir, et al.
Published: (2018-02-01)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
by: Oliver Neuhaus, et al.
Published: (2021-03-01)

Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months Tolerabilidade, eventos adversos e aderência ao acetato de glatiramer em 28 pacientes com esclerose múltipla usando a droga continuamente por pelo menos seis meses
by: Ana Patricia Perez Fiore, et al.
Published: (2005-09-01)

Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System?
by: Thomas Vorup-Jensen, et al.
Published: (2012-11-01)

Glatiramer acetate 40 mg/ml: A review of the results of GALA and GLACIER clinical studies
by: N. Yu. Lashch, et al.
Published: (2016-07-01)

Deficits in Monocyte Function in Age Related Macular Degeneration: A Novel Systemic Change Associated With the Disease
by: Ben J. Gu, et al.
Published: (2021-03-01)

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
by: Giannini Marta, et al.
Published: (2012-10-01)

Non-biological complex drugs and their analogues in the pathogenetic therapy of multiple sclerosis: Issues of efficacy and safety in clinical use
by: I. D. Stolyarov, et al.
Published: (2015-03-01)

A case of Disseminated Herpes Zoster in a patient with Multiple Sclerosis on Glatiramer acetate
by: C. Halasan, et al.
Published: (2020-01-01)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
by: Iftach Sagy, et al.
Published: (2016-04-01)

Pharmaceutical dosage forms of biological and other drugs used in the treatment of multiple sclerosis
by: Savić Snežana, et al.
Published: (2015-01-01)

Novel approaches in the treatment of multiple sclerosis
by: Stepanović-Petrović Radica, et al.
Published: (2015-01-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
by: Lyubomira Vlahova, et al.
Published: (2021-02-01)

Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System
by: Kim M. A. De Kleijn, et al.
Published: (2020-06-01)

Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients
by: Chiara Zecca, et al.
Published: (2019-07-01)

The Novel Effect of Immunomodulator-Glatiramer Acetate on Epileptogenesis and Epileptic Seizures
by: Ming-Chi Lai, et al.
Published: (2018-10-01)

Glatiramer Acetate, Dimethyl Fumarate and Monomethyl Fumarate Up-Regulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance their Chemotaxis and Cytotoxicity. Implications for Cancer Immunotherapy
by: Azzam Maghazachi, et al.
Published: (2016-10-01)

Estudio comparativo de melatonina contra los tratamientos inmunomoduladores (interferón beta y acetato de glatirámero) en un modelo murino de esclerosis múltiple
by: E.J. Ramos González, et al.
Published: (2021-05-01)

Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
by: Judith Steinberg, et al.
Published: (2019-05-01)

Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
by: Jan W. Traub, et al.
Published: (2019-11-01)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
by: Gianluca Furneri, et al.
Published: (2019-06-01)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
by: Oreja-Guevara Celia, et al.
Published: (2012-09-01)

Comparison of first-line therapies for relapsing-remitting multiple sclerosis
by: Yennam, Amulya
Published: (2021)

Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS
by: Christine Haenggeli, et al.
Published: (2007-04-01)

WHAT IS THERAPEUTIC EQUIVALENCE OF GENERIC DRUG AND HOW TO PROVE IT
by: N. P. Kutishenko, et al.
Published: (2016-01-01)

Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis
by: Jimmy Y. Song, et al.
Published: (2021-01-01)

The immunomodulator glatiramer acetate influences spinal motoneuron plasticity during the course of multiple sclerosis in an animal model
by: K.B. Marques, et al.
Published: (2009-02-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
by: Arthur Komlosh, et al.
Published: (2019-07-01)

Disease-modifying agents in multiple sclerosis
by: Coyle P
Published: (2009-01-01)

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
by: Colin J. Ross, et al.
Published: (2017-05-01)

Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report
by: Joanna Roskal-Wałek, et al.
Published: (2021-09-01)

Statistical considerations of noninferiority, bioequivalence and equivalence testing in biosimilars studies
by: Xu, Siyan
Published: (2016)

TREATMENT OF OSTEOPOROSIS: CLINICAL EXPERIENCE IN USING A GENERIC DRU
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-03-01)

TREATMENT OF OSTEOPOROSIS: CLINICAL EXPERIENCE IN USING A GENERIC DRU
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-03-01)

Assessment of the Feasibility of Therapeutic Equivalence Studies
by: D. V. Goryachev, et al.
Published: (2019-06-01)

Development of an UPLC-MS/MS Method for Quantitative Analysis of Clotrimazole in Human Plasma Samples
by: Lucia Lisi, et al.
Published: (2020-11-01)

Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus
by: Nabil A. Alhakamy, et al.
Published: (2021-02-01)

Cannot write session to /tmp/vufind_sessions/sess_0h1cl25cb92mr8sjsd14a28u5u